AJMC® Peer Exchange® peer-to-peer panel discussions feature authoritative insights, opinions, and perspectives on important issues facing today’s managed care professionals.
April 22nd 2022Managed Care Perspectives: Optimizing Women’s Reproductive Health
A panel of experts provide an overview of the burden of common health concerns in women’s reproductive years, review currently available treatment options, and discuss a personalized treatment approach for women’s reproductive health. Ryan Haumschild, PharmD, MBA, MS, discusses implications of the Affordable Care Act (ACA) to women’s reproductive health, along with methods to ensure timely access to appropriate therapy.
March 25th 2022Improving Access to Alternative Therapies for Treatment Resistant Depression
A panel of experts explore the patient journey and unmet needs of patients with treatment resistant depression (TRD), outline treatment strategies for TRD outside of oral antidepressants/antipsychotics and explore strategies to support access to these alternative therapies through improved billing/coding strategies.
December 21st 2021Treating Wet Age-Related Macular Degeneration and Diabetic Macular Edema
Jim Kenney, RPh, MBA; Kevin U. Stephens, Sr, JD, MD; Philip Niles, MD, MBA; and Nicholas G. Anderson, MD, review the clinical and economic burden of wet AMD and diabetic macular edema (DME), share currently available treatment options, and discuss considerations for emerging ophthalmic therapies.
August 30th 2021 Reducing Alzheimer’s Disease Burden Through Early Diagnosis and Treatment
A panel of experts highlight the burden of Alzheimer’s disease and current unmet needs related to diagnosis and treatment, discuss clinical and payer considerations for the diagnosis and management of AD, and generate discussion around future directions in the diagnosis and treatment.
August 11th 2021Population Health Implications of Cardiorenal Metabolic Syndrome
Neil Minkoff, MD; Nihar R. Desai, MD, MPH; Jeffrey Turner, MD; and Om P. Ganda, MD, explore opportunities for improving population health outcomes in cardiorenal metabolic syndrome, including clinical and payer considerations of emerging diabetes treatments.